Briefing Summary: US FDA Posts Advisory Committee Materials for Amgen’s REPATHA for High Cholesterol – JUN 10, 2015 (EMDAC)

The US FDA has posted details, including company and FDA Briefing Materials, for the Wednesday, June 10, 2015 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Committee Meeting. The Committee will discuss the safety and efficacy of REPATHA (Evolocumab) for injection, submitted by Amgen Inc. for the treatment of high cholesterol (BLA Number 125522).

See the SAC Tracker report